About NuVasive (NASDAQ:NUVA)
NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800
Debt
Debt-to-Equity Ratio0.73%
Current Ratio3.48%
Quick Ratio1.94%
Price-To-Earnings
Trailing P/E Ratio27.91
Forward P/E Ratio21.67
P/E Growth1.4
Sales & Book Value
Annual Sales$1.03 billion
Price / Sales2.65
Cash Flow$4.8376 per share
Price / Cash11.02
Book Value$15.68 per share
Price / Book3.40
Profitability
EPS (Most Recent Fiscal Year)$1.91
Net Income$83 million
Net Margins8.06%
Return on Equity13.40%
Return on Assets6.20%
Miscellaneous
Employees2,600
Outstanding Shares51,260,000
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive announced that its board has authorized a stock repurchase plan on Wednesday, October 25th 2017, which allows the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Monday, February, 26th. The medical device company reported $0.56 EPS for the quarter, hitting analysts' consensus estimates of $0.56. The medical device company had revenue of $271.70 million for the quarter, compared to analysts' expectations of $272.11 million. NuVasive had a return on equity of 13.40% and a net margin of 8.06%. The firm's revenue for the quarter was up .2% on a year-over-year basis. During the same period last year, the company earned $0.53 earnings per share. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
What guidance has NuVasive issued on next quarter's earnings?
NuVasive issued an update on its FY18 earnings guidance on Monday, February, 26th. The company provided earnings per share (EPS) guidance of $2.44-2.47 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.34. The company issued revenue guidance of $1.095-1.105 billion, compared to the consensus revenue estimate of $1.09 billion.
What price target have analysts set for NUVA?
16 brokerages have issued 1-year target prices for NuVasive's shares. Their forecasts range from $47.00 to $90.00. On average, they anticipate NuVasive's share price to reach $66.80 in the next year. View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. According to Zacks Investment Research, "NuVasive's recent quarterly performances were promising significantly driven by solid international growth. The last-reported third quarter marked the fourth consecutive one registering more than 20% growth in international business. However, overall sales in the quarter were impacted by procedural volume-related challenges in the United States and the adverse impact of hurricanes Harvey and Irma on NuVasive’s U.S. results and Maria on the international front. With chances of fourth-quarter revenues being affected by Maria in Puerto Rico and with the anticipated lower U.S. procedural volumes to continue, NuVasive is pressed to reduce its full-year guidance, which is disappointing. Also, the contraction in gross margin is a matter of concern. Overall, for the past six months, NuVasive has been trading below the broader industry." (2/20/2018)
- 2. Needham & Company LLC analysts commented, "We are upgrading NUVA to Buy from Underperform since: 1) we believe that consensus revenue and EPS estimates have declined to levels that are more realistic and likely conservative, 2) NUVA has done several acquisitions that probably aren’t fully factored into consensus revenue or EPS estimates (Vertera and SafePassage, which we estimate could add ~2% to NUVA’s 2018 revenue), 3) NUVA should see a significant benefit from tax reform (which we expect to increase its EPS by ~15% in 2018), and 4) we think NUVA shares are attractively valued considering the expected benefit from tax reform. We have raised our revenue and EPS estimates to reflect recent deals and tax reform." (1/4/2018)
- 3. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)
Are investors shorting NuVasive?
NuVasive saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 6,729,507 shares, an increase of 44.4% from the March 30th total of 4,659,516 shares. Based on an average trading volume of 888,518 shares, the short-interest ratio is presently 7.6 days. Currently, 13.3% of the shares of the company are sold short.
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), Nevro (NVRO), Merit Medical Systems (MMSI), NovoCure (NVCR), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Intersect ENT (XENT) and ATRION (ATRI).
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. Gregory T. Lucier, Chairman & CEO (Age 54)
- Mr. Matthew W. Link, Exec. VP of Strategy, Technology & Corp. Devel. (Age 43)
- Mr. Jason Marshall Hannon, Former Pres & COO (Age 46)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 51)
- Mr. Jereme Sylvain, Chief Accounting Officer (Age 38)
Has NuVasive been receiving favorable news coverage?
Media coverage about NUVA stock has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuVasive earned a news impact score of 0.15 on Accern's scale. They also assigned news articles about the medical device company an impact score of 45.34 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $53.31.
How big of a company is NuVasive?
NuVasive has a market capitalization of $2.68 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.91 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
NuVasive (NASDAQ:NUVA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for NuVasive in the last 12 months. Their average twelve-month price target is $66.80, suggesting that the stock has a possible upside of 25.30%. The high price target for NUVA is $90.00 and the low price target for NUVA is $47.00. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.69 | 2.73 | 2.81 | 2.76 |
| Ratings Breakdown: | 0 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $66.80 | $68.2143 | $72.3333 | $72.6667 |
| Price Target Upside: | 25.30% upside | 40.79% upside | 39.13% upside | 33.11% upside |
NuVasive (NASDAQ:NUVA) Consensus Price Target History
NuVasive (NASDAQ:NUVA) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
NuVasive (NASDAQ:NUVA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NuVasive (NASDAQ NUVA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.20%
NuVasive (NASDAQ NUVA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/6/2018 | Gregory T Lucier | CEO | Buy | 6,000 | $50.30 | $301,800.00 | |  |
| 3/1/2018 | Gregory T Lucier | CEO | Buy | 6,000 | $48.57 | $291,420.00 | | |
| 8/29/2017 | Gregory T Lucier | CEO | Buy | 2,000 | $61.52 | $123,040.00 | | |
| 8/18/2017 | Lesley H. Howe | Director | Sell | 3,970 | $64.64 | $256,620.80 | | |
| 8/17/2017 | Gregory T Lucier | CEO | Buy | 5,000 | $66.22 | $331,100.00 | | |
| 8/1/2017 | Peter Michael Leddy | EVP | Buy | 7,850 | $63.88 | $501,458.00 | | |
| 3/8/2017 | Jason Hannon | Insider | Sell | 24,840 | $74.22 | $1,843,624.80 | | |
| 2/14/2017 | Lesley H. Howe | Director | Sell | 6,049 | $73.26 | $443,149.74 | | |
| 12/12/2016 | Matthew Link | Insider | Sell | 10,303 | $67.99 | $700,500.97 | | |
| 11/4/2016 | Michael D Ohalleran | Director | Buy | 4,200 | $58.26 | $244,692.00 | | |
| 11/2/2016 | Patrick Miles | Director | Buy | 16,967 | $58.97 | $1,000,543.99 | | |
| 11/1/2016 | Patrick Miles | Director | Buy | 16,667 | $59.00 | $983,353.00 | | |
| 10/31/2016 | Joan Stafslien | EVP | Buy | 5,000 | $59.68 | $298,400.00 | | |
| 10/31/2016 | Michael D Ohalleran | Director | Buy | 4,205 | $59.47 | $250,071.35 | | |
| 8/23/2016 | Jason Hannon | EVP | Sell | 2,625 | $64.80 | $170,100.00 | | |
| 8/2/2016 | Jason Hannon | EVP | Sell | 11,184 | $62.70 | $701,236.80 | | |
| 8/2/2016 | Lesley H. Howe | Director | Sell | 3,602 | $62.44 | $224,908.88 | | |
| 7/20/2016 | Jason Hannon | EVP | Sell | 2,920 | $62.80 | $183,376.00 | | |
| 6/16/2016 | Jason Hannon | EVP | Sell | 14,534 | $57.57 | $836,722.38 | 37,616 | |
| 1/6/2016 | Patrick Miles | COO | Sell | 10,723 | $54.03 | $579,363.69 | 31,646 | |
| 12/16/2015 | Patrick Miles | COO | Sell | 9,127 | $52.56 | $479,715.12 | 31,646 | |
| 12/7/2015 | Quentin S Blackford | CFO | Sell | 15,000 | $51.10 | $766,500.00 | 2,599 | |
| 12/3/2015 | Patrick Miles | COO | Sell | 5,873 | $52.51 | $308,391.23 | 40,773 | |
| 11/2/2015 | Patrick Miles | COO | Sell | 15,000 | $48.12 | $721,800.00 | 32,627 | |
| 10/5/2015 | Matthew Link | insider | Sell | 1,714 | $50.72 | $86,934.08 | 53,089 | |
| 10/3/2015 | Quentin S Blackford | CFO | Sell | 5,000 | $36.30 | $181,500.00 | | |
| 10/1/2015 | Patrick Miles | COO | Sell | 15,000 | $48.10 | $721,500.00 | 47,627 | |
| 9/8/2015 | Russell Powers | EVP | Sell | 5,806 | $51.64 | $299,821.84 | 62,024 | |
| 9/2/2015 | Jason Hannon | EVP | Sell | 11,962 | $52.02 | $622,263.24 | 18,565 | |
| 9/1/2015 | Patrick Miles | COO | Sell | 15,000 | $52.03 | $780,450.00 | 62,627 | |
| 8/31/2015 | Patrick Miles | COO | Sell | 15,000 | $53.34 | $800,100.00 | 62,627 | |
| 7/20/2015 | Jason Hannon | EVP | Sell | 15,000 | $49.60 | $744,000.00 | | |
| 6/15/2015 | Gregory T Lucier | CEO | Buy | 4,491 | $49.49 | $222,259.59 | | |
| 6/12/2015 | Gregory T Lucier | CEO | Buy | 8,000 | $50.10 | $400,800.00 | | |
| 6/10/2015 | Gregory T Lucier | CEO | Buy | 10,000 | $49.10 | $491,000.00 | | |
| 6/8/2015 | Gregory T Lucier | CEO | Buy | 10,000 | $49.26 | $492,600.00 | | |
| 6/4/2015 | Gregory T Lucier | CEO | Buy | 10,000 | $49.71 | $497,100.00 | | |
| 6/2/2015 | Gregory T Lucier | CEO | Buy | 8,000 | $49.96 | $399,680.00 | | |
| 6/2/2015 | Patrick Miles | COO | Sell | 4,194 | $49.47 | $207,477.18 | | |
| 5/29/2015 | Jack R Blair | Director | Sell | 3,703 | $50.16 | $185,742.48 | | |
| 5/28/2015 | Gregory T Lucier | CEO | Buy | 34,000 | $49.25 | $1,674,500.00 | | |
| 5/28/2015 | Russell Powers | EVP | Sell | 8,042 | $49.00 | $394,058.00 | | |
| 5/19/2015 | Patrick Miles | COO | Sell | 15,000 | $47.52 | $712,800.00 | | |
| 5/1/2015 | Russell Powers | EVP | Sell | 11,881 | $45.21 | $537,140.01 | | |
| 4/24/2015 | Russell Powers | EVP | Sell | 3,888 | $44.07 | $171,344.16 | | |
| 3/13/2015 | Patrick Miles | COO | Sell | 7,920 | $45.52 | $360,518.40 | | |
| 3/9/2015 | Alexis V Lukianov | CEO | Sell | 5,313 | $44.82 | $238,128.66 | | |
| 3/3/2015 | Matthew Link | Insider | Sell | 7,500 | $44.46 | $333,450.00 | | |
| 3/2/2015 | Jason Hannon | EVP | Sell | 5,085 | $45.06 | $229,130.10 | | |
| 2/9/2015 | Alexis V Lukianov | CEO | Sell | 5,454 | $46.10 | $251,429.40 | | |
| 2/5/2015 | Matthew Link | Insider | Sell | 4,078 | $45.77 | $186,650.06 | | |
| 2/3/2015 | Patrick Miles | COO | Sell | 15,000 | $45.53 | $682,950.00 | | |
| 1/28/2015 | Keith Valentine | COO | Sell | 6,970 | $46.96 | $327,311.20 | | |
| 1/12/2015 | Alexis V Lukianov | CEO | Sell | 7,452 | $49.69 | $370,289.88 | | |
| 1/5/2015 | Jason Hannon | EVP | Sell | 12,117 | $46.82 | $567,317.94 | | |
| 1/5/2015 | Patrick Miles | Insider | Sell | 15,000 | $46.61 | $699,150.00 | | |
| 12/30/2014 | Jason Hannon | EVP | Sell | 15,000 | $47.63 | $714,450.00 | | |
| 12/29/2014 | Jason Hannon | EVP | Sell | 3,146 | $47.57 | $149,655.22 | | |
| 12/24/2014 | Patrick Miles | Insider | Sell | 15,000 | $47.52 | $712,800.00 | | |
| 12/19/2014 | Keith Valentine | COO | Sell | 5,893 | $47.78 | $281,567.54 | | |
| 12/1/2014 | Keith Valentine | COO | Sell | 2,500 | $43.66 | $109,150.00 | | |
| 11/19/2014 | Keith Valentine | COO | Sell | 5,582 | $43.32 | $241,812.24 | | |
| 11/19/2014 | Quentin S Blackford | CFO | Sell | 7,698 | $43.41 | $334,170.18 | | |
| 11/7/2014 | Alexis V Lukianov | CEO | Sell | 25,000 | $41.40 | $1,035,000.00 | | |
| 11/3/2014 | Keith Valentine | COO | Sell | 2,500 | $40.61 | $101,525.00 | | |
| 10/2/2014 | Keith Valentine | COO | Sell | 2,500 | $35.00 | $87,500.00 | | |
| 9/2/2014 | Keith Valentine | COO | Sell | 2,500 | $35.14 | $87,850.00 | | |
| 8/1/2014 | Keith Valentine | COO | Sell | 2,500 | $37.11 | $92,775.00 | | |
| 8/1/2014 | Michael Lambert | CFO | Sell | 4,010 | $37.11 | $148,811.10 | | |
| 7/30/2014 | Jason Hannon | EVP | Sell | 5,000 | $39.00 | $195,000.00 | | |
| 7/10/2014 | Russell Powers | EVP | Sell | 3,200 | $33.43 | $106,976.00 | | |
| 7/1/2014 | Keith Valentine | COO | Sell | 2,500 | $35.65 | $89,125.00 | | |
| 7/1/2014 | Michael Lambert | CFO | Sell | 23,225 | $35.48 | $824,023.00 | | |
| 6/20/2014 | Keith Valentine | COO | Sell | 5,000 | $35.00 | $175,000.00 | | |
| 6/20/2014 | Russell Powers | EVP | Sell | 9,526 | $35.00 | $333,410.00 | | |
| 5/5/2014 | Robert Hunt | Director | Sell | 20,000 | $34.25 | $685,000.00 | 34,500 | |
| 5/2/2014 | Michael Lambert | CFO | Sell | 13,096 | $33.07 | $433,084.72 | 51,695 | |
| 4/1/2014 | Keith Valentine | COO | Sell | 2,500 | $38.41 | $96,025.00 | 88,985 | |
| 3/11/2014 | Peter Farrell | Director | Sell | 48,000 | $36.88 | $1,770,240.00 | 6,794 | |
| 1/21/2014 | Jason Hannon | EVP | Sell | 10,095 | $36.60 | $369,477.00 | 8,899 | |
| 1/16/2014 | Keith Valentine | COO | Sell | 20,000 | $37.96 | $759,200.00 | 44,226 | |
| 1/7/2014 | Alexis Lukianov | CEO | Sell | 34,217 | $34.29 | $1,173,300.93 | 55,740 | |
| 1/7/2014 | Craig Hunsaker | SVP | Sell | 4,980 | $35.00 | $174,300.00 | 21,142 | |
| 12/30/2013 | Craig Hunsaker | SVP | Sell | 4,275 | $32.10 | $137,227.50 | 24,980 | |
| 12/23/2013 | Michael Lambert | CFO | Sell | 17,091 | $32.49 | $555,286.59 | 13,096 | |
| 11/7/2013 | Alexis Lukianov | CEO | Sell | 5,000 | $31.45 | $157,250.00 | 72,827 | |
| 10/30/2013 | Jason Hannon | EVP | Sell | 2,334 | $28.90 | $67,452.60 | | |
| 10/30/2013 | Patrick Miles | Insider | Sell | 21,223 | $31.10 | $660,035.30 | | |
| 10/28/2013 | Patrick Miles | Insider | Sell | 7,331 | $25.72 | $188,553.32 | | |
| 10/21/2013 | Russell Powers | VP | Sell | 12,500 | $25.39 | $317,375.00 | | |
| 10/11/2013 | Jason Hannon | EVP | Sell | 1,000 | $26.00 | $26,000.00 | 19,991 | |
| 10/7/2013 | Jason Hannon | EVP | Sell | 8,705 | $23.99 | $208,832.95 | 19,991 | |
| 10/7/2013 | Michael Lambert | CFO | Sell | 15,442 | $24.04 | $371,225.68 | 30,187 | |
| 8/6/2013 | Richard Treharne III | Director | Buy | 2,000 | $23.26 | $46,520.00 | | |
| 7/12/2013 | Craig E Hunsaker | SVP | Sell | 2,000 | $27.00 | $54,000.00 | | |
| 7/8/2013 | Alexis V Lukianov | CEO | Sell | 5,000 | $25.74 | $128,700.00 | | |
| 7/1/2013 | Keith Valentine | COO | Sell | 1,698 | $25.00 | $42,450.00 | | |
| 5/13/2013 | Alexis V Lukianov | CEO | Sell | 7,500 | $22.71 | $170,325.00 | | |
| 5/8/2013 | Peter Michael Leddy | Director | Buy | 2,400 | $22.24 | $53,376.00 | | |
| 5/7/2013 | Alexis V Lukianov | CEO | Sell | 12,500 | $22.11 | $276,375.00 | | |
(Data available from 1/1/2013 forward)
NuVasive (NASDAQ NUVA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | NuVasive, Inc. (NUVA) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 26 at 2:22 AM |
 | NuVasive Sponsors AANS 2018, Hosts Workshops And Presentations On Latest Innovations
finance.yahoo.com - April 24 at 5:01 PM |
| NuVasive (NUVA) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - April 24 at 9:36 AM |
| NuVasive (NUVA) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 21 at 7:24 AM |
 | New Research: Key Drivers of Growth for NuVasive, Apptio, Apollo Investment, Uranium Energy, AECOM, and US ...
globenewswire.com - April 19 at 9:00 AM |
| Investors Purchase Large Volume of Put Options on NuVasive (NUVA)
www.americanbankingnews.com - April 19 at 8:32 AM |
| NuVasive, Inc. (NUVA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 7:24 PM |
| NuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $260.48 Million
www.americanbankingnews.com - April 17 at 2:17 AM |
| NuVasive, Inc. (NUVA) Expected to Announce Earnings of $0.45 Per Share
www.americanbankingnews.com - April 15 at 9:22 PM |
| NuVasive (NUVA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 9:51 PM |
| NuVasive (NUVA) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM |
| NuVasive Announces Conference Call And Webcast Of First Quarter 2018 Results
finance.yahoo.com - April 10 at 4:51 PM |
| Royal Bank of Canada Reiterates "Buy" Rating for NuVasive (NUVA)
www.americanbankingnews.com - April 7 at 8:19 PM |
| TheStreet Lowers NuVasive (NUVA) to C+
www.americanbankingnews.com - April 6 at 10:22 PM |
| NuVasive Sponsors ISASS 2018, Hosts Workshops And Presentations
finance.yahoo.com - April 5 at 4:45 PM |
| NuVasive (NUVA) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - April 5 at 4:38 PM |
| NuVasive (NUVA) Given a $78.00 Price Target by JPMorgan Chase Analysts
www.americanbankingnews.com - April 5 at 4:08 PM |
| NuVasive (NUVA) Given a $74.00 Price Target by BTIG Research Analysts
www.americanbankingnews.com - April 5 at 2:58 PM |
| NuVasive (NUVA) Now Covered by Analysts at Goldman Sachs
www.americanbankingnews.com - April 4 at 8:04 AM |
| NuVasive Portfolio Now Includes ALIF Retractor Platform For Lateral And Supine Approaches
finance.yahoo.com - April 2 at 4:52 PM |
| $260.48 Million in Sales Expected for NuVasive, Inc. (NUVA) This Quarter
www.americanbankingnews.com - April 1 at 8:23 AM |
| Needham & Company LLC Upgrades NuVasive (NUVA) to Buy
www.americanbankingnews.com - March 30 at 5:08 PM |
| $0.45 EPS Expected for NuVasive, Inc. (NUVA) This Quarter
www.americanbankingnews.com - March 30 at 1:18 AM |
| Research Shows NuVasive Porous PEEK Structure Maintains High Porosity After Impaction
finance.yahoo.com - March 29 at 4:49 PM |
| Why Is NuVasive (NUVA) Up 4.6% Since Its Last Earnings Report?
finance.yahoo.com - March 28 at 4:46 PM |
| NuVasive (NUVA) Rating Lowered to Market Perform at Wells Fargo
www.americanbankingnews.com - March 27 at 7:26 PM |
 | Global Artificial Spinal Disc Market 2014-2018 & 2024 - Key Players are AxioMed, Simplify Medical, K2M, Spinal ...
www.benzinga.com - March 27 at 4:43 PM |
| NuVasive (NUVA) Cut to "Market Perform" at Leerink Swann
www.americanbankingnews.com - March 25 at 10:56 PM |
| BidaskClub Upgrades NuVasive (NUVA) to "Hold"
www.americanbankingnews.com - March 24 at 1:17 PM |
| Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
finance.yahoo.com - March 19 at 4:42 PM |
| Cryolife (CRY) & NuVasive (NUVA) Head-To-Head Review
www.americanbankingnews.com - March 16 at 12:31 PM |
| NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $260.59 Million
www.americanbankingnews.com - March 14 at 4:58 AM |
| Financial Survey: NuVasive (NUVA) versus Cryolife (CRY)
www.americanbankingnews.com - March 10 at 5:06 PM |
| Gregory T. Lucier Purchases 6,000 Shares of NuVasive, Inc. (NUVA) Stock
www.americanbankingnews.com - March 8 at 6:45 PM |
| NuVasive Gains From International Business Amid Pricing Woes
finance.yahoo.com - March 7 at 5:41 PM |
| NuVasive, Inc. (NUVA) is Tamarack Advisers LP's 5th Largest Position
www.americanbankingnews.com - March 6 at 10:30 AM |
| Axa Boosts Holdings in NuVasive, Inc. (NUVA)
www.americanbankingnews.com - March 6 at 4:46 AM |
| Insider Buying: NuVasive, Inc. (NUVA) CEO Acquires 6,000 Shares of Stock
www.americanbankingnews.com - March 5 at 7:00 PM |
| NuVasive to Participate in Investor Events in March 2018
finance.yahoo.com - March 5 at 5:20 PM |
| NuVasive, Inc. (NUVA) Expected to Earn FY2018 Earnings of $2.45 Per Share
www.americanbankingnews.com - March 5 at 5:22 AM |
| ValuEngine Downgrades NuVasive (NUVA) to Sell
www.americanbankingnews.com - March 4 at 1:58 PM |
| NuVasive, Inc. (NUVA) Stake Raised by Teacher Retirement System of Texas
www.americanbankingnews.com - March 4 at 7:06 AM |
| NuVasive (NUVA) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - March 3 at 10:34 PM |
| Broadfin Capital LLC Has $4.80 Million Stake in NuVasive, Inc. (NUVA)
www.americanbankingnews.com - March 3 at 4:53 AM |
| Gabelli Brokers Boost Earnings Estimates for NuVasive, Inc. (NUVA)
www.americanbankingnews.com - March 2 at 4:04 PM |
| NuVasive, Inc. (NUVA) Shares Bought by Altrinsic Global Advisors LLC
www.americanbankingnews.com - March 2 at 4:10 AM |
| NuVasive, Inc. (NUVA) Position Raised by Swiss National Bank
www.americanbankingnews.com - March 1 at 5:42 PM |
| Q4 2018 EPS Estimates for NuVasive, Inc. Boosted by Analyst (NUVA)
www.americanbankingnews.com - March 1 at 1:30 PM |
| NuVasive, Inc. (NUVA) Forecasted to Earn Q1 2018 Earnings of $0.49 Per Share
www.americanbankingnews.com - March 1 at 7:30 AM |
| Q1 2018 EPS Estimates for NuVasive, Inc. (NUVA) Lifted by Leerink Swann
www.americanbankingnews.com - March 1 at 7:30 AM |
NuVasive (NASDAQ:NUVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NuVasive (NASDAQ:NUVA) Income Statement, Balance Sheet and Cash Flow Statement
NuVasive (NASDAQ NUVA) Stock Chart for Thursday, April, 26, 2018
Loading chart…
